7AdvancedExamHealth

Financial Incentives for GPs Spark Debate on Obesity Drug Prescriptions

The UK government is offering general practitioners up to £3,000 in bonuses to increase prescriptions of the weight loss drug Mounjaro, backed by £25 million in ring-fenced funding. This unprecedented inclusion of weight loss medications in the GP contract has ignited a complex debate about equitable healthcare access, medical ethics, and the most effective approaches to tackling the national obesity crisis.

2 min readLevel 7February 24, 2026

By Flalingo Editorial Team

Vocabulary

Study these words before reading the article. Click the audio button to hear pronunciation.

incentivise

/ɪnˈsentɪvaɪz/

verb

To encourage or motivate someone to do something by offering them a reward or benefit

“The government decided to incentivise renewable energy adoption through generous tax reductions for homeowners.”

eligibility

/ˌelɪdʒəˈbɪləti/

noun

The state of having the right to receive or do something because one meets the required conditions

“The eligibility criteria for the scholarship require applicants to demonstrate both academic excellence and financial need.”

disparity

/dɪˈspærəti/

noun

A great and often unfair difference between two or more things or groups

“Researchers have documented a growing disparity in healthcare outcomes between affluent and disadvantaged communities.”

scrutiny

/ˈskruːtəni/

noun

Careful and thorough examination or observation of something

“The proposed legislation came under intense scrutiny from opposition members during the parliamentary debate.”

commodifying

/kəˈmɒdɪfaɪɪŋ/

verb

Treating something that should not be traded as if it were a product to be bought and sold

“Many academics have expressed concern about the trend of commodifying higher education through excessive tuition fees.”

pragmatic

/præɡˈmætɪk/

adjective

Dealing with problems in a practical and sensible way rather than following fixed theories or ideals

“The minister adopted a pragmatic approach to immigration reform, focusing on achievable policy changes rather than ideological goals.”

Listen to Article

0:00 / 0:00

Article

Click on any underlined word to see its definition. Highlighted words are from the vocabulary section.

Seldom has a public health initiative generated such contentious discourse as the decision to incentivise obesity drug prescriptions. The English government has introduced financial bonuses of up to £3,000 for general practitioners who maximise prescriptions of Mounjaro. This policy, backed by £25 million in dedicated funding, marks the first time weight loss drugs have been incorporated into the GP contract. Health Secretary Wes Streeting has argued that access to these medications should be determined by clinical need, not wealth.

Mounjaro, known generically as tirzepatide, is a once-weekly injectable medication that mimics gut hormones to suppress appetite. The NHS has prioritised approximately 220,000 patients for the drug within the first three years of its phased rollout. Currently, eligibility remains tightly restricted to severely obese adults with a BMI exceeding 40 and at least four weight-related conditions. From the next financial year, however, the threshold is expected to drop to a BMI of 35.

The rationale underpinning this initiative is fundamentally one of equity. An estimated 2.4 million people are already taking weight loss drugs in the United Kingdom, with most accessing treatment privately. The government contends that financial incentives will address the disparity between those who can afford private prescriptions and those who cannot. Not all GP practices have been prescribing the medication, despite eligible patients awaiting treatment.

Nevertheless, the programme has attracted considerable scrutiny from medical professionals and policy analysts alike. The Royal College of GPs has emphasised that doctors do not prescribe based on financial incentives. Critics warn that such bonuses risk commodifying clinical decisions and diverting attention from structural causes of obesity. Furthermore, experts caution that patients who discontinue the drug typically regain approximately two-thirds of the weight they lost.

What distinguishes this policy from previous obesity strategies is its integration of pharmaceutical intervention with primary care infrastructure. Proponents argue it represents a pragmatic response to a crisis costing the NHS an estimated £11 billion annually. Yet sceptics maintain that sustainable progress demands addressing socioeconomic determinants of obesity, not merely its symptoms. Whether financial incentives ultimately enhance or undermine the integrity of clinical practice remains an open question.

Comprehension Quiz

Test your understanding of the article with these multiple-choice questions.

1
What is the maximum bonus GPs can receive for prescribing Mounjaro under the new scheme?
2
How many patients has the NHS prioritised for Mounjaro in the first three years?
3
What is the current minimum BMI required for NHS eligibility for Mounjaro?
4
What proportion of lost weight do patients typically regain after discontinuing the drug?
5
What is the total ring-fenced funding allocated to support the new GP obesity indicators?

Discussion

Answer these comprehension questions about the article.

1
According to the article, what is the primary justification the government provides for offering financial bonuses to GPs?
2
The author suggests that the Royal College of GPs responded to the incentive scheme with a particular concern. What was it, and why is it significant?
3
What evidence does the article present to support the claim that there is an inequality in access to weight loss drugs in the UK?
4
According to the passage, what potential risk do critics associate with patients who stop taking Mounjaro?
5
How does the article characterise the tension between pharmaceutical intervention and addressing the structural causes of obesity?

Further Discussion

Share your opinions on these open-ended questions.

1
To what extent do you believe financial incentives for doctors can coexist with ethical medical practice, and where should the line be drawn?
2
In your country, how is obesity addressed as a public health issue, and do you think the approach is effective?
3
Some argue that weight loss drugs treat symptoms rather than root causes. Do you agree, and what alternative policies would you propose?
4
Should access to expensive medical treatments be determined solely by clinical need, or are there circumstances where economic productivity should also be considered?
5
If you were advising a government on tackling an obesity crisis, would you prioritise pharmaceutical solutions, preventive education, or regulatory measures on the food industry? Justify your reasoning.